



Biotech Daily

Thursday July 14, 2022

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: STARPHARMA UP 9%; PATRYS DOWN 8%**
- * **COMPUMEDICS UNAUDITED REVENUE UP 4% TO \$37m; SALES UP 29%**
- * **USPTO ALLOWS CYNATA STEM CELLS FOR ASTHMA PATENT**
- * **GENETIC TECHNOLOGIES COMPLETES AFFINITY DNA ACQUISITION**
- * **ADMINISTRATORS EXTEND OVENTUS CONVENING PERIOD**
- * **CORRECTION: ZELIRA**
- * **CLARIFICATION: MACH7 TECHNOLOGIES**
- * **NEUROTECH APPOINTS GERALD QUIGLEY DIRECTOR**
- * **CRESO IMPACTIVE APPOINTS 3 MARIJUANA 'BRAND AMBASSADORS'**

MARKET REPORT

The Australian stock market was up 0.44 percent on Thursday July 14, 2022, with the ASX200 up 29.0 points to 6,650.6 points.

Twenty-six of the Biotech Daily Top 40 stocks were up, 10 fell and four traded unchanged. All three Big Caps were up.

Starpharma was the best, up six cents or 8.9 percent to 73.5 cents, with 393,627 shares traded; followed by Imugene up 8.7 percent to 25 cents, with 41.1 million shares traded.

Compumedics and Dimerix climbed more than seven percent; Actinogen and Telix were up more than five percent; Alcidion, Clinuvel, Emvision, Mesoblast, Resonance and Volpara improved four percent or more; Amplia, Cochlear, Immutep, Nanosonics and Oncosil were up more than three percent; Antisense and Pro Medicus rose more than two percent; Avita, Cynata, Genetic Signatures, Impedimed, Neuren, Paradigm and Resmed were up one percent or more; with CSL, Opthea and Polynovo up less than one percent.

Patrys led the falls, down 0.2 cents or 8.3 percent to 2.2 cents, with 1.5 million shares traded. Micro-X lost 6.45 percent; Kazia fell 4.9 percent; Prescient was down three percent; Cyclopharm and Proteomics shed more than two percent; Atomo, Pharmaxis and Orthocell were down more than one percent; with Next Science down by less than one percent.

COMPUMEDICS

Compumedics says unaudited revenue for the year to June 30, 2022 was up four percent to \$37 million, on sales orders up 29 percent to \$45.6 million.

Compumedics said sales orders for its sleep, brain and ultrasonic blood-flow monitoring applications was up 29 percent on the previous corresponding period to a record \$45.6 million.

The company said that not all new sales orders received in the year to June 30, 2022 could be shipped and booked as revenue because of global supply issues, chip shortages/delays and other Covid-19 pandemic-related factors, but it expected these issues to abate and for shipping to return to normal over the next year.

Compumedics said that a \$4.1 million magneto-encephalography (MEG) order secured with China's Tianjin Normal University in January was expected to be completed late in 2022 or early 2023, with revenue expected at that time.

The company said that the difference between sales and revenue related to timing of payments.

Compumedics said it had record cash of \$7.2 million at June 30, 2022.

The company said that with its unused banking facilities the cash and equivalents came to a total of about \$9.8 million, and its net cash position was about \$1.2 million on June 30, 2022 compared to \$1.8 million at June 30, 2021.

Compumedics was up 1.5 cents or 7.7 percent to 21 cents.

CYNATA THERAPEUTICS

Cynata says the US Patent and Trademark Office has given a notice of allowance for a patent protecting its Cymerus mesenchymal stem cell technology for asthma.

Cynata said the patent, titled 'Method for Treating Allergic Airways Disease (AAD)/Asthma', would protect the technology until August 31, 2038.

The company said it expected the patent would be granted in October 2022.

Cynata said that inventors of the use of the Cymerus mesenchymal stem cells (MSCs) for asthma and allergic airways disease were Monash Biomedicine Institute's Prof Chrisan Samuel and Monash University's Dr Simon Royce.

Cynata chief executive officer Dr Ross Macdonald said the company was "delighted that Prof Samuel's investigations around the utility of Cynata's proprietary MSCs in lung disease has resulted in yet a further patent, particularly in the ... US".

"This new milestone builds on our portfolio of wholly-Cynata owned patents and patent applications, providing further protection over our proprietary Cymerus technology to 2038 and beyond, particularly in the field of diseases of the lungs," Dr Macdonald said.

Cynata was up half a cent or 1.3 percent to 38 cents.

GENETIC TECHNOLOGIES

Genetic Technologies says it has completed its acquisition of the Brighton, England-based electronic-commerce business, Affinity DNA.

In May, Genetic Technologies said it would acquire the company for GBP555,000 (\$A985,383) on or before May 31, 2022 (BD: May 16, 2022).

Today, Genetic Technologies chief executive officer Simon Morriss said the acquisition "builds on our direct-to-consumer sales channel and supports the promotion of the Genetype Multi Risk test for serious disease across our target markets worldwide".

Genetic Technologies was up 0.05 cents or 16.7 percent to 0.35 cents with 10.5 million shares traded.

OVENTUS MEDICAL, GRANT THORNTON ADMINISTRATORS

Grant Thornton as administrators of Oventus says the Federal Court of Australia has extended the convening period by six months to January 12, 2023.

In an email, the administrators said that prior to the extension, the second meetings of creditors were due to be held by July 19, 2022 but the Court ordered the meetings “may be held at any time during, or within five business days after ... the convening period”. Grant Thornton said that the extension of the convening period would allow “sufficient time for a recapitalization of Oventus Medical to take place or, failing this, for the sale of the companies’ business and/or assets to occur”.

The administrators said no further action was required from creditors at this stage.

In an announcement to the ASX, Grant Thornton said that it had a “deferral of financial reporting obligations” with relief granted under an Australian Securities and Investments Commission instrument, which provided for “the deferral of financial reporting obligations for a minimum period of six months from the date of appointment of administrators and up to a maximum of 24 months if the administration continues for longer than six months”.

Grant Thornton said that “under the Instrument all financial reporting obligations of the company are deferred until at least December 14, 2022”.

The administrators said all outstanding financial reports would “need to be lodged with ASIC and released to the ASX as a condition of the reinstatement to quotation”.

Grant Thornton said that the company’s annual general meeting had been deferred until within two months after the end of the deferral period.

For further information email: Oventus@au.gt.com.

Oventus last traded at two cents.

CORRECTION: ZELIRA THERAPEUTICS

Last night’s article on Zelira carried an incorrect headline – Zelira To ASX: ‘German Marijuana Okay Pushed Price 94%’ – and first sentence.

The article later made it clear that Zelira “was in the process of preparing an announcement in relation to this matter, and was relying on [ASX] Listing Rule 3.1A.2 not to announce that information under Listing Rule 3.1 on the basis that a very limited number of employees within the company were in possession of the information and the company considered the information to be confidential”.

The headline should have said: Zelira To ASX: ‘More Buyers Than Sellers Pushed Price 94%’.

The first sentence should have been: “Zelira has told the ASX that more buyers than sellers may have pushed its share price 94.1 percent, as investors began to better understand the company.”

In its response to the ASX query, Zelira said the price movement “was most likely driven by an increase in small volume buyers being met by a reduction in small volume sellers”, as investors began “to identify the unique investment opportunity Zelira’s multiple shots on goal strategy presents”.

In its query, the ASX said that Zelira’s shares rose 94.1 percent from \$1.02 on July 6 to \$1.98 on July 12, 2022, prior to the pause in trading and subsequent trading halt, and prior to announcing German regulatory approval for its marijuana-based Zenivol for insomnia.

The mistake was made by the Wednesday sub-editor, who claimed that he was still recovering from contracting Covid-19 four weeks earlier and had been feeling very tired.

He has been dismissed and can enjoy a good lie-down at his leisure.

We apologize unreservedly to Zelira for the error.

Zelira was up a further 99 cents or 44.2 percent to \$3.23.

CLARIFICATION: MACH7 TECHNOLOGIES

Mach 7 says the US District Court for the District of Delaware dismissal of all AI visualize claims was received on July 8, 2022, rather than June 8, 2022.

Yesterday, Mach7 said that Delaware US District Court granted its request to dismiss all claims made by the Plano, Texas-based AI Visualize on June 8 (BD: Jul 13, 2022).

Mach7 fell 1.5 cents or 2.4 percent to 61 cents.

NEUROTECH INTERNATIONAL

In an Appendix 3X initial director's interest notice Gerald Quigley says he was appointed a non-executive director, effective from July 7, 2022.

On page four of a 14-page announcement regarding the results of its marijuana-based NTI164 for paediatric autism spectrum disorder, last week, Neurotech said Mr Quigley was a pharmacist and consumer health commentator who had published extensively on the role of natural extracts in regulating inflammation (BD: Jul 8, 2022).

Neurotech was up 0.3 cents or 4.3 percent to 7.3 cents.

CRESO PHARMA

Creso says its Canadian subsidiary Impactive has appointed three "brand ambassadors" for its marijuana-based Impactive cannabidiol pain relief.

Creso said the brand ambassadors were golfers Kelly Whaley and Will Wilcox, and "performance coach" Troy Van Biezen.

The company said its agreements with Ms Whaley, Mr Wilcox and Mr Van Biezen also stipulated that they would "continue to be provided product for both personal and professional use ... [and] work with the Impactive marketing team in order to create a library of uniquely branded content including videos, photographs, social media post templates, and sponsored content".

Creso said Ms Whaley would receive \$US7,500 for an initial term of six months, Mr Wilcox would receive \$US6,000 for 12 months and Mr Van Biezen would receive \$US25,000 in cash and 100,000 shares, with a further up to 2,000,000 "performance rights" pending sales hurdles and shareholder approval.

Creso was up 0.2 cents or 5.1 percent to 4.1 cents with 1.4 million shares traded.